Management of Bone Disease and Body Composition Changes

  • Author: Donald P. Kotler, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 5/7/18 (What's New)

Summary

    Epidemiology and Mechanisms of Bone Disease in HIV-Infected Patients
    • Many studies have documented an increased prevalence of both osteopenia and osteoporosis in HIV-infected individuals[Brown 2006]
    • Prevalence of osteopenia was evaluated in the SUN cohort, who were compared with non–HIV-infected matched controls enrolled in NHANES[Overton 2007]
      • Higher prevalence of lower BMD was found in the HIV-infected cohort compared with the NHANES cohort
    Osteopenia Associated With Antiretroviral Medications
      Effect of ART vs No ART
        Effect of Tenofovir DF
          Effect of Tenofovir AF vs Tenofovir DF
            Effect of Other Regimens
              Other Factors
                Summary

              Action required

              Keywords: Bone Disease

              ©2020 Clinical Care Options, LLC. All Rights Reserved.

              The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.